TG Therapeutics (TGTX) AI Stock Analysis

• Market Cap: $5.93B
• Dividend Yield: N/A
• Average Volume (3M): 2.46M
• Price to Earnings (P/E): 147.6
• Beta (1Y): 1.57
• Revenue Growth: 33.54%
• EPS Growth: -6.13%
• Country: US
• Employees: 352
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): 0.03
• Shares Outstanding: 158,755,040
• 10 Day Avg. Volume: 1,884,447
• 30 Day Avg. Volume: 2,455,645
• PEG Ratio: 0.18
• Price to Book (P/B): -1.05
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.09
• Enterprise Value/Market Cap: 0.27
• Enterprise Value/Revenue: 1.19
• Enterprise Value/Gross Profit: 4.69
• Enterprise Value/Ebitda: 6.76
• 1Y Price Target: $41.60
• Price Target Upside: 15.52% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 64 Neutral
• Price Target: $39.00 ▲(8.30%Upside)

TG Therapeutics' score is driven by strong earnings call results and improving financial performance, despite challenges in cash flow and high valuation. The technical analysis indicates a neutral market position, contributing to the moderate overall score.

Positive Factors

Market Expansion

Briumvi is now commercially available in additional countries in the EU, UK, and Switzerland, which could translate into incrementally larger royalty revenue in the quarters ahead.

Revenue Growth

The company has substantially increased its full-year US net Briumvi revenue guidance, reflecting strong growth expectations.

Stock Performance

TGTX shares are trading up +5.4% after Roche announced that the phase 3 MUSETTE study failed to demonstrate a significant benefit for high-dose Ocrevus over the currently approved 600 mg dose.

Negative Factors

Competitor Risk

Ocrevus Zunovo still remains a bigger risk to Briumvi growth.

Financial Outlook

Analyst reiterates Underperform and $11 price objective on, in their view, an overvalued long-term market opportunity for Briumvi with key challenges to competitive pillars ahead.

Prescription Trends

This is the first time repeat prescriptions have surpassed new prescriptions, potentially indicating a slowdown in new start growth.

TG Therapeutics Business Overview & Revenue Model

Company Description

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

How the Company Makes Money

TG Therapeutics generates revenue through the sales of its pharmaceutical products, primarily focusing on innovative treatments for B-cell malignancies and autoimmune diseases. The company's revenue model is centered around the commercialization of its core products, which are developed through extensive research and clinical trials. Key revenue streams include product sales upon obtaining regulatory approval and entering the market. Additionally, TG Therapeutics may engage in strategic partnerships or collaborations with other pharmaceutical companies to enhance the development and distribution of its products, thereby contributing to its earnings. These partnerships may also involve licensing agreements, milestone payments, and royalties, which can provide additional financial support and revenue opportunities.

TG Therapeutics Financial Statement Overview

Summary

TG Therapeutics exhibits a strong recovery trajectory with significant revenue and profit growth, alongside improved balance sheet metrics. However, the continued negative operating cash flow and historical financial instability present areas of concern. Overall, the company shows promise but faces challenges in achieving sustainable cash flow generation.

Income Statement

TG Therapeutics has demonstrated strong revenue growth with a significant increase from $278,500 in 2022 to $386.4 million in TTM (Trailing-Twelve-Months). The gross profit margin improved to 87.4% in TTM, and net profit margin also rose to 10.1%, signaling enhanced operational efficiency. However, the past losses in earlier years indicate historical instability.

Balance Sheet

The company has managed to improve its financial health with positive stockholders' equity of $237.3 million in TTM. The debt-to-equity ratio is low at 0.038, indicating low leverage. However, the equity ratio of 36.1% suggests moderate reliance on liabilities, and past negative equity highlights previous financial distress.

Cash Flow

The operating cash flow remains negative at -$61 million in TTM, though free cash flow has shown improvement. The company's ability to convert net income into cash flow is limited, posing a risk to liquidity despite substantial financing activities that sustain operations.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
386.39M	329.00M	233.66M	2.79M	6.69M	152.00K
	Gross Profit
337.80M	290.52M	219.11M	2.52M	5.90M	-222.00K
	EBIT
59.82M	41.93M	20.63M	-192.84M	-344.77M	-273.59M
	EBITDA
70.06M	49.90M	26.10M	-187.63M	-341.97M	-272.68M
	Net Income Common Stockholders
39.15M	23.38M	12.67M	-203.83M	-355.55M	-285.88M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
276.24M	311.00M	217.51M	174.08M	350.30M	605.43M
	Total Assets
656.69M	577.69M	329.59M	193.57M	379.63M	625.64M
	Total Debt
254.58M	254.38M	110.80M	83.06M	79.05M	41.98M
	Net Debt
-123.16M	73.83M	17.86M	-19.24M	-219.84M	-511.46M
	Total Liabilities
419.40M	355.33M	169.09M	134.99M	142.48M	106.29M
	Stockholders Equity
237.29M	222.36M	160.50M	-1.53B	-1.33B	519.35M
Cash Flow		Free Cash Flow
-61.09M	-40.56M	-31.41M	-176.18M	-296.04M	-214.86M
	Operating Cash Flow
-61.02M	-40.52M	-31.41M	-176.17M	-295.63M	-214.51M
	Investing Cash Flow
-4.71M	-1.04M	-50.65M	-20.01M	-332.00K	-24.51M
	Financing Cash Flow
122.42M	128.53M	72.70M	-391.00K	41.42M	679.83M

TG Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 36.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TGTX, the sentiment is Negative. The current price of 36.01 is below the 20-day moving average (MA) of 36.43, below the 50-day MA of 37.34, and above the 200-day MA of 31.82, indicating a neutral trend. The MACD of 0.35 indicates Negative momentum. The RSI at 45.35 is Neutral, neither overbought nor oversold. The STOCH value of 39.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TGTX.

TG Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KRYS	71 Outperform	$4.06B	33.01	13.90%	―	247.53%	118.34%
TGTX	64 Neutral	$5.93B	147.58	19.70%	―	33.54%	-6.13%
SRPT	56 Neutral	$3.72B	19.61	-23.61%	―	59.15%	-1881.09%
AXSM	54 Neutral	$5.32B	―	-282.16%	―	72.16%	9.65%
Sector *	54 Neutral	$5.41B	3.27	-45.10%	3.29%	16.81%	0.02%
LEGN	53 Neutral	$6.98B	―	-20.00%	―	112.46%	54.33%
BPMC	50 Neutral	$8.29B	―	-47.71%	―	99.19%	48.43%

TG Therapeutics Corporate Events

TG Therapeutics Approves Key Proposals at Annual Meeting

On June 12, 2025, TG Therapeutics, Inc. held its Annual Meeting where stockholders representing 74.58% of the outstanding shares were present. All proposals, including the election of six directors, ratification of KPMG LLP as the independent auditor, approval of executive compensation, and amendment to the 2022 Incentive Plan, were approved, potentially impacting the company’s governance and financial strategies.

The most recent analyst rating on (TGTX) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on TG Therapeutics stock, see the TGTX Stock Forecast page.